Developer docs
API playgroundTry for free, no card

Search company profiles

OneVentures

Full company profile

uuid00009mx

Namestring
OneVentures
Legal namestring
OneVentures Pty Ltd
Company typeenum
Private
Founded yearint
2010
Descriptiontext

OneVentures is a Sydney-headquartered, Australian venture capital firm founded in 2010 that manages over A$1B in Funds Under Management across seven funds organised around three investment pillars: Growth Equity (Series A+ venture equity for transformative technology companies, particularly B2B SaaS), Growth Credit (A$1–20M covenant-light venture debt facilities to scaling tech companies generating >A$3–5M recurring revenue), and Healthcare (venture equity for clinical-stage healthcare and biotech companies with first/best-in-class products addressing large unmet needs). A state-focused Victorian Growth Fund overlays the Growth Equity and Credit mandates for the Victorian market. The firm invests directly through its own application and referral pipeline, with no intermediaries, and sources capital from wholesale and institutional investors via a Dynamo investor portal and direct outreach.

The firm's core differentiator is its hands-on operating model: OneVentures embeds operating partners, former operators and C-suite executives (former CEOs of Vodafone Hutchison Australia, 3 Mobile and Fairfax Digital; senior executives from eBay Australia, KPMG, McKinsey, Bristol-Myers Squibb and Sandoz/Novartis) into portfolio companies alongside capital, and senior partners chair or sit on portfolio boards. Notable portfolio outcomes include Employment Hero (reached a A$2B valuation; 13x return to OneVentures), Phocas Software (acquired by Accel-KKR for over A$500M, ~7x return / ~A$120M to investors), Eucalyptus (sold to a New York-listed healthcare giant for A$1.6B), Vaxxas (needle-free HD-MAP vaccine patch technology partnered with the Gates Foundation, WHO and BARDA), BiVACOR (first-in-human Total Artificial Heart implantation; A$100M 2025 raise), Buildkite, Fleet Space Technologies, and Lumary. The firm also developed an ESG_VC framework with the Australian Investment Council to standardise ESG measurement across its portfolio.

Commercially, OneVentures generates revenue through three streams: recurring management fees on committed or invested capital across its seven funds, recurring interest income from Growth Credit amortising loans, and lumpy carried interest from successful portfolio exits. Distribution is concentrated in Australia and New Zealand with portfolio companies scaling globally across the US, UK and Southeast Asia. The firm maintains offices in Sydney (HQ) and Melbourne, employs an estimated 40–60 staff across investment, operations and finance functions, and has been recognised on The Australian's Top 100 Innovators list (2024, 2025) and as an Australian Investment Council Investing for Growth award winner in 2024 and 2025.

Short descriptiontext

OneVentures is an Australian later-stage venture capital firm managing over A$1B across seven funds, investing growth equity, venture credit and healthcare capital into scaling technology and biotech companies in Australia and New Zealand with hands-on operational support.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSydney, Australia
HQ citystring
Sydney
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
venture capital, growth equity, venture debt, healthcare investment, private equity
Industry3 codes
PRIMARYFSANAAAB
Early-Stage Venture Capital (Series A/B)
SECONDARYFSANAAAL
Venture Debt Providers
SECONDARYFSAHAJAD
Direct Lending — Venture Debt
Financial & Insurance/Hedge Funds & Alternative Investments/Alternative Investments — Private Credit & Direct Lending
NAICS code2 codes
  • Portfolio Management and Investment Advice52394
  • Other Investment Pools and Funds5259
SIC code2 codes
  • Investment Advice6282
  • Short-Term Business Credit Institutions6153
Product category
Venture Capital and Growth Equity
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Management Fees
TypeSubscription Recurring
Description

VC firms typically charge annual management fees on funds under management (FUM), calculated as a percentage of committed capital or invested value, providing recurring revenue stream.

one-ventures.com.au
2Carried Interest (Performance Fees)
TypeLicensing Royalties
Description

OneVentures generates carried interest from successful exits of portfolio companies, with notable returns including 13x on Employment Hero and 7x on Phocas. The firm has delivered over $1B in returns to investors, indicating substantial carried interest generation.

one-ventures.com.au
3Growth Credit Interest Income
TypeSubscription Recurring
Description

Growth Credit Fund provides debt facilities of $1-$20M to portfolio companies, generating interest income on amortising loans over 3-4 years. The fund is covenant light with minimal dilution via warrants, providing a recurring interest revenue stream.

one-ventures.com.au
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure, Others
Pricing details1 tier
1Growth Credit facilities ranging from $1M to $20M
ModelSubscriptionBilling cadencePay-as-you-go
Notes

Facilities of $1-$20M; funding can be upfront or tranched over time; amortising loans over 3-4 years with interest-only periods available; tailored to business and covenant light; no Director Guarantees; minimal dilution via warrants (typically <0.5% of cap table).

one-ventures.com.au
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

OneVentures is a later-stage venture capital firm providing growth equity, venture credit, and healthcare venture equity financing to scaling technology and clinical-stage healthcare companies in Australia and New Zealand. The firm manages over $1B across seven funds and partners hands-on with portfolio companies, providing capital alongside operational, strategic, and international expansion expertise.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Over $1B in returns delivered to investors
+4 more records
Product overview1 text field

OneVentures is a later-stage venture capital firm offering multiple investment fund products: Growth Equity (for Series A+ technology companies), Growth Credit (debt financing for scaling tech companies with facilities of $1-20M), Healthcare Fund (equity for clinical-stage healthcare/biotech companies), and the Victorian Growth Fund (regional focus). The firm manages over $1B in FUM across seven funds and provides hands-on operational and strategic support to portfolio companies rather than passive investment.

Product and service5 records
1Growth Equity Fund
CategoryInvestment Fund
Description

Venture equity financing for transformative technology companies at Series A+ stage, focusing on B2B SaaS and technology companies ready to scale, including AI, workplace digitisation, blockchain, digital twins, autonomous systems, cleantech, and education technology. Provides hands-on operational and international expansion support alongside capital.

2Growth Credit Fund
CategoryInvestment Fund
Description

Debt financing for scaling technology companies, providing flexible venture credit facilities of $1-20M to support growth capital with limited dilution, extending runway to next funding round, or funding acquisitions. Facilities are amortising loans over 3-4 years with interest-only options, covenant-light, no Director Guarantees, and minimal dilution via warrants (typically <0.5% of cap table).

3Healthcare Fund
CategoryInvestment Fund
Description

Venture equity financing for advancing healthcare and biotech companies developing transformative technology with global reach and impact, targeting first or best-in-class products addressing large unmet medical needs. Targets clinical-stage or near-clinical companies with clear regulatory and reimbursement paths.

4Victorian Growth Fund (VGF)
CategoryInvestment Fund
Description

A state-focused fund investing in Victoria's most promising scale-up companies, part of OneVentures' Growth Equity and Credit strategy. Led by Principal Justine Carzino.

5Growth Fund VII
CategoryInvestment Fund
Description

Seventh OneVentures fund, raising $200 million to fill the gap left by corporate venture capital funds and to continue growth equity investments in transformative technology companies.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2025-12-09
Description

OneVentures partnered with Fishburners' The Ascent Project, a free year-round program supporting women founders in accessing capital through education and network connections. The initiative, built on two pillars of funding education and investor access, has partnered with over 30 organizations including venture funds Airtree, Tractor Ventures, OneVentures, Tidal, Touch Ventures, Side Stage, Techstars, and Birchal. The program will be available to women founders nationwide from early 2026 at no cost.

Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

The Bill & Melinda Gates Foundation has partnered with Vaxxas (a OneVentures portfolio company) to support the development of needle-free vaccine delivery technology with global health impact, particularly for developing world populations.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

WHO has partnered with Vaxxas (a OneVentures portfolio company) on the development and deployment of needle-free vaccine delivery technology to improve global vaccination accessibility.

4US Department of Health Biomedical Advanced Research and Development Authority (BARDA)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

BARDA has partnered with Vaxxas (a OneVentures portfolio company) to support the advancement of needle-free vaccine patch technology for pandemic preparedness and public health applications.

one-ventures.com.au
Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeRegional player
Description

Australian early-to-growth-stage venture capital firm investing in ANZ tech companies. Comparable on ANZ focus and stage mandate, though typically smaller ticket sizes than OneVentures' Growth Equity and Credit funds.

TypeDirect peer
Description

One of Australia's largest venture capital firms, investing across seed to growth in Australian and NZ tech companies. Directly comparable to OneVentures on geography, stage focus (Series A+), sector breadth (B2B SaaS, fintech, healthcare), and active later-stage investing.

TypeDirect peer
Description

Australia- and Israel-focused growth-stage venture capital firm with multiple funds and over A$1B in AUM. Directly comparable to OneVentures on growth-stage mandate, ANZ base, multi-fund platform, and Series A+ B2B/fintech/SaaS focus.

TypeDirect peer
Description

Leading Australian VC firm investing from pre-seed through Series B in ANZ startups. Comparable on ANZ focus, sector breadth (B2B SaaS, deep tech), and stage coverage, though Blackbird skews earlier than OneVentures' growth focus.

TypeDirect peer
Description

ASX-listed technology investment company focused on later-stage, expansion-stage Australian and NZ tech companies. Direct comparable on ANZ focus, later-stage ticket sizes, and recurring revenue SaaS/tech thesis — and notably a prior employer of OneVentures' Partner Bevin Shields.

TypeDirect peer
Description

Australian deep tech and science-backed venture firm, manager of the CSIRO Innovation Fund. Comparable on ANZ base and dedicated deep tech/biotech thesis, partially overlapping with OneVentures' Healthcare Fund.

TypeRegional player
Description

ANZ-based early-to-growth-stage VC firm investing in B2B SaaS, fintech, and digital platforms. Comparable on ANZ focus and tech mandate; overlaps with OneVentures on Series A+ B2B SaaS investing.

TypeRegional player
Description

Australian growth-equity investor focused on later-stage technology and tech-enabled businesses. Comparable on ANZ base and growth-stage mandate, though broader sector mandate including non-tech-enabled businesses.

TypeOthers
Description

Global technology-focused private equity and growth equity firm that acquired OneVentures' portfolio company Phocas Software for ~$500M. Comparable as a co-investor and acquirer of growth-stage tech companies and indirect participant in OneVentures' exit ecosystem.

TypeOthers
Description

Global growth-stage venture capital firm that co-invested with OneVentures in Employment Hero. Comparable as a co-investor in OneVentures' portfolio and a benchmark for global Series A+ growth equity scale, though materially larger in AUM and global reach.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment78 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

OneVentures

Venture Capital and Growth Equityone-ventures.com.au

OneVentures is an Australian later-stage venture capital firm managing over A$1B across seven funds, investing growth equity, venture credit and healthcare capital into scaling technology and biotech companies in Australia and New Zealand with hands-on operational support.

What OneVentures does

OneVentures is a Sydney-headquartered, Australian venture capital firm founded in 2010 that manages over A$1B in Funds Under Management across seven funds organised around three investment pillars: Growth Equity (Series A+ venture equity for transformative technology companies, particularly B2B SaaS), Growth Credit (A$1–20M covenant-light venture debt facilities to scaling tech companies generating >A$3–5M recurring revenue), and Healthcare (venture equity for clinical-stage healthcare and biotech companies with first/best-in-class products addressing large unmet needs). A state-focused Victorian Growth Fund overlays the Growth Equity and Credit mandates for the Victorian market. The firm invests directly through its own application and referral pipeline, with no intermediaries, and sources capital from wholesale and institutional investors via a Dynamo investor portal and direct outreach.

The firm's core differentiator is its hands-on operating model: OneVentures embeds operating partners, former operators and C-suite executives (former CEOs of Vodafone Hutchison Australia, 3 Mobile and Fairfax Digital; senior executives from eBay Australia, KPMG, McKinsey, Bristol-Myers Squibb and Sandoz/Novartis) into portfolio companies alongside capital, and senior partners chair or sit on portfolio boards. Notable portfolio outcomes include Employment Hero (reached a A$2B valuation; 13x return to OneVentures), Phocas Software (acquired by Accel-KKR for over A$500M, ~7x return / ~A$120M to investors), Eucalyptus (sold to a New York-listed healthcare giant for A$1.6B), Vaxxas (needle-free HD-MAP vaccine patch technology partnered with the Gates Foundation, WHO and BARDA), BiVACOR (first-in-human Total Artificial Heart implantation; A$100M 2025 raise), Buildkite, Fleet Space Technologies, and Lumary. The firm also developed an ESG_VC framework with the Australian Investment Council to standardise ESG measurement across its portfolio.

Commercially, OneVentures generates revenue through three streams: recurring management fees on committed or invested capital across its seven funds, recurring interest income from Growth Credit amortising loans, and lumpy carried interest from successful portfolio exits. Distribution is concentrated in Australia and New Zealand with portfolio companies scaling globally across the US, UK and Southeast Asia. The firm maintains offices in Sydney (HQ) and Melbourne, employs an estimated 40–60 staff across investment, operations and finance functions, and has been recognised on The Australian's Top 100 Innovators list (2024, 2025) and as an Australian Investment Council Investing for Growth award winner in 2024 and 2025.

OneVentures firmographics

Firmographics
Name
OneVentures
Legal name
OneVentures Pty Ltd
Website
https://one-ventures.com.au
Company type
Private
Founded year
2010
Operating status
Operating
Headcount range
11–50 employees
Short description
OneVentures is an Australian later-stage venture capital firm managing over A$1B across seven funds, investing growth equity, venture credit and healthcare capital into scaling technology and biotech companies in Australia and New Zealand with hands-on operational support.
Ownership category
akta.pro rank

OneVentures industry classification

Industry
Product category
Venture Capital and Growth Equity
NAICS
Portfolio Management and Investment Advice (52394), Other Investment Pools and Funds (5259)
SIC
Investment Advice (6282), Short-Term Business Credit Institutions (6153)
akta.pro industry
PRIMARYFSANAAAB
Early-Stage Venture Capital (Series A/B)
SECONDARYFSANAAAL
Venture Debt Providers
SECONDARYFSAHAJAD
Direct Lending — Venture Debt
Financial & Insurance/Hedge Funds & Alternative Investments/Alternative Investments — Private Credit & Direct Lending

Keywords

  • Venture capital
  • Growth equity
  • Venture debt
  • Healthcare investment
  • Private equity

Where OneVentures is headquartered

Location

Headquarters

HQ city
Sydney
HQ country
Australia
HQ region
Oceania

Offices2 records

Markets served

OneVentures business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure, Others

Revenue model

  1. Management Fees: VC firms typically charge annual management fees on funds under management (FUM), calculated as a percentage of committed capital or invested value, providing recurring revenue stream.
  2. Carried Interest (Performance Fees): OneVentures generates carried interest from successful exits of portfolio companies, with notable returns including 13x on Employment Hero and 7x on Phocas. The firm has delivered over $1B in returns to investors, indicating substantial carried interest generation.
  3. Growth Credit Interest Income: Growth Credit Fund provides debt facilities of $1-$20M to portfolio companies, generating interest income on amortising loans over 3-4 years. The fund is covenant light with minimal dilution via warrants, providing a recurring interest revenue stream.

Pricing tiers

ModelBillingPrice
SubscriptionPay-as-you-goGrowth Credit facilities ranging from $1M to $20M

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

OneVentures product offering

Product offering

Core offering

OneVentures is a later-stage venture capital firm providing growth equity, venture credit, and healthcare venture equity financing to scaling technology and clinical-stage healthcare companies in Australia and New Zealand. The firm manages over $1B across seven funds and partners hands-on with portfolio companies, providing capital alongside operational, strategic, and international expansion expertise.

Product overview

OneVentures is a later-stage venture capital firm offering multiple investment fund products: Growth Equity (for Series A+ technology companies), Growth Credit (debt financing for scaling tech companies with facilities of $1-20M), Healthcare Fund (equity for clinical-stage healthcare/biotech companies), and the Victorian Growth Fund (regional focus). The firm manages over $1B in FUM across seven funds and provides hands-on operational and strategic support to portfolio companies rather than passive investment.

Differentiator

Problem solved

Functional benefit

Products and services

  • Growth Equity Fund Venture equity financing for transformative technology companies at Series A+ stage, focusing on B2B SaaS and technology companies ready to scale, including AI, workplace digitisation, blockchain, digital twins, autonomous systems, cleantech, and education technology. Provides hands-on operational and international expansion support alongside capital.
  • Growth Credit Fund Debt financing for scaling technology companies, providing flexible venture credit facilities of $1-20M to support growth capital with limited dilution, extending runway to next funding round, or funding acquisitions. Facilities are amortising loans over 3-4 years with interest-only options, covenant-light, no Director Guarantees, and minimal dilution via warrants (typically <0.5% of cap table).
  • Healthcare Fund Venture equity financing for advancing healthcare and biotech companies developing transformative technology with global reach and impact, targeting first or best-in-class products addressing large unmet medical needs. Targets clinical-stage or near-clinical companies with clear regulatory and reimbursement paths.
  • Victorian Growth Fund (VGF) A state-focused fund investing in Victoria's most promising scale-up companies, part of OneVentures' Growth Equity and Credit strategy. Led by Principal Justine Carzino.
  • Growth Fund VII Seventh OneVentures fund, raising $200 million to fill the gap left by corporate venture capital funds and to continue growth equity investments in transformative technology companies.

Quantifiable outcome

  • Over $1B in returns delivered to investors
  • +4 more outcomes

Companies that use OneVentures

Customer profile

Named customers8 records

Segments3 records

Ideal customer profiles4 records

OneVentures technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

OneVentures partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered minor, flagship and core.

  • Fishburners / The Ascent ProjectminorGTM or Marketing Partner · 9 December 2025OneVentures partnered with Fishburners' The Ascent Project, a free year-round program supporting women founders in accessing capital through education and network connections. The initiative, built on two pillars of funding education and investor access, has partnered with over 30 organizations including venture funds Airtree, Tractor Ventures, OneVentures, Tidal, Touch Ventures, Side Stage, Techstars, and Birchal. The program will be available to women founders nationwide from early 2026 at no cost.
  • Bill & Melinda Gates FoundationflagshipStrategic or Co-development PartnerThe Bill & Melinda Gates Foundation has partnered with Vaxxas (a OneVentures portfolio company) to support the development of needle-free vaccine delivery technology with global health impact, particularly for developing world populations.
  • World Health Organisation (WHO)coreStrategic or Co-development PartnerWHO has partnered with Vaxxas (a OneVentures portfolio company) on the development and deployment of needle-free vaccine delivery technology to improve global vaccination accessibility.
  • US Department of Health Biomedical Advanced Research and Development Authority (BARDA)coreStrategic or Co-development PartnerBARDA has partnered with Vaxxas (a OneVentures portfolio company) to support the advancement of needle-free vaccine patch technology for pandemic preparedness and public health applications.

Scale indicators9 records

Recent moves9 records

Expansion highlights6 records

OneVentures competitors and assessment

Company assessment

Regional players

  • Carthona Capital: Australian early-to-growth-stage venture capital firm investing in ANZ tech companies. Comparable on ANZ focus and stage mandate, though typically smaller ticket sizes than OneVentures' Growth Equity and Credit funds.
  • Folklore Ventures: ANZ-based early-to-growth-stage VC firm investing in B2B SaaS, fintech, and digital platforms. Comparable on ANZ focus and tech mandate; overlaps with OneVentures on Series A+ B2B SaaS investing.
  • Equity Venture Partners (EVP): Australian growth-equity investor focused on later-stage technology and tech-enabled businesses. Comparable on ANZ base and growth-stage mandate, though broader sector mandate including non-tech-enabled businesses.

Direct peers

  • AirTree Ventures: One of Australia's largest venture capital firms, investing across seed to growth in Australian and NZ tech companies. Directly comparable to OneVentures on geography, stage focus (Series A+), sector breadth (B2B SaaS, fintech, healthcare), and active later-stage investing.
  • Square Peg Capital: Australia- and Israel-focused growth-stage venture capital firm with multiple funds and over A$1B in AUM. Directly comparable to OneVentures on growth-stage mandate, ANZ base, multi-fund platform, and Series A+ B2B/fintech/SaaS focus.
  • Blackbird Ventures: Leading Australian VC firm investing from pre-seed through Series B in ANZ startups. Comparable on ANZ focus, sector breadth (B2B SaaS, deep tech), and stage coverage, though Blackbird skews earlier than OneVentures' growth focus.
  • Bailador Technology Investments: ASX-listed technology investment company focused on later-stage, expansion-stage Australian and NZ tech companies. Direct comparable on ANZ focus, later-stage ticket sizes, and recurring revenue SaaS/tech thesis — and notably a prior employer of OneVentures' Partner Bevin Shields.
  • Main Sequence Ventures: Australian deep tech and science-backed venture firm, manager of the CSIRO Innovation Fund. Comparable on ANZ base and dedicated deep tech/biotech thesis, partially overlapping with OneVentures' Healthcare Fund.

Others

  • Accel-KKR: Global technology-focused private equity and growth equity firm that acquired OneVentures' portfolio company Phocas Software for ~$500M. Comparable as a co-investor and acquirer of growth-stage tech companies and indirect participant in OneVentures' exit ecosystem.
  • Insight Partners: Global growth-stage venture capital firm that co-invested with OneVentures in Employment Hero. Comparable as a co-investor in OneVentures' portfolio and a benchmark for global Series A+ growth equity scale, though materially larger in AUM and global reach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

OneVentures social profiles

Digital presence

OneVentures financial estimates

Financial estimate

Revenue estimate

Valuation estimate

OneVentures leadership team

Management profile

Number of profiles

Profiles12 records

OneVentures subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

OneVentures funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

OneVentures M&A and investment

M&A and investment

M&A

Investments78 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OneVentures

What does OneVentures do?

OneVentures is a later-stage venture capital firm providing growth equity, venture credit, and healthcare venture equity financing to scaling technology and clinical-stage healthcare companies in Australia and New Zealand. The firm manages over $1B across seven funds and partners hands-on with portfolio companies, providing capital alongside operational, strategic, and international expansion expertise.

Is OneVentures a public or private company?

OneVentures is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was OneVentures founded?

OneVentures was founded in 2010. It employs 11 to 50 people.

Where is OneVentures based?

OneVentures is headquartered in Sydney, Australia, in the Oceania region.

How does OneVentures make money?

Three revenue lines are on record. Management Fees are the primary driver. The others are carried Interest (Performance Fees) and growth Credit Interest Income.

Who are OneVentures's main competitors?

Regional players on record are Carthona Capital, Folklore Ventures and Equity Venture Partners (EVP). Direct peers are AirTree Ventures, Square Peg Capital, Blackbird Ventures, Bailador Technology Investments and Main Sequence Ventures. Others are Accel-KKR and Insight Partners.

Does OneVentures have an API?

No public API is recorded for OneVentures.

What industry is OneVentures in?

OneVentures's product category is Venture Capital and Growth Equity. Its primary akta.pro industry code is FSANAAAB, Early-Stage Venture Capital (Series A/B), with a secondary code of FSANAAAL, Venture Debt Providers. Its NAICS code is 52394 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Startup DailyRole Call: OneVentures, Affinda, DX1, BeforePay, Roblox, AI ambassadorSix new appointments were announced: Derek Bopping as Australia's cyber and AI ambassador, Tim Hope as DX1's tech chief, James Hird as Affinda's sports head, Ian Anderson as OneVentures' capital director, Kasey Kaplan as Beforepay's CEO, and Joel Neoh as Roblox's MD for SEA and Oceania. The roles span cybersecurity, technology, sports, venture capital, fintech, and gaming.LinkedInTruescope Joins OneVentures Growth Credit PortfolioOneVentures has made a Growth Credit investment in Truescope, an AI-powered media intelligence platform that aggregates and analyzes media signals to provide organizational insights. The investment will support Truescope's global growth strategy and continued advancement of its platform technology. The deal involved collaboration between OneVentures, Truescope CEO John Croll AM, and Scale Ventures.VerteroVertero Unveils New Strategic Direction Focused on Breaking Barriers in Neurodegenerative DiseasesAxial Therapeutics has rebranded as Vertero Therapeutics, a biotechnology company pioneering treatments for neurodegenerative diseases by targeting peripheral drivers rather than focusing solely on the brain. The company announced its lead candidate VT-5006, a first-in-class gut-selective small molecule designed to slow Parkinson's disease progression, which is on track to begin Phase 1 clinical trials in Q4 2025, supported by $20 million in Series D financing raised in 2025. Founded in 2016 out of Caltech, Vertero is building a pipeline of oral small molecule therapeutics targeting peripheral drivers of neurodegenerative diseases, with investors including OneVentures and Seventure.LinkedIn2023 was a big year for OneVentures and our portfolio, here's a few highlights! ⭐ We added six team members. 🔬 We welcomed ImmVirX to our Fund III portfolio. ❤️ BiVACOR Inc received FDA approval…OneVentures highlighted several key achievements from its portfolio companies in 2023, including funding rounds and regulatory approvals. Notable events include BiVACOR Inc receiving FDA approval for a Total Artificial Heart study and Employment Hero securing $263 million in Series F funding.Australian Financial ReviewOneVentures-backed start-up Coassemble hangs for-sale signCoassemble, a Newcastle learning software start-up backed by OneVentures and EVP, has entered a formal sale process after receiving unsolicited approaches. It received non-binding indicative bids from strategics but has not selected an offer, and it engaged Tiger & Bear Partners to vet proposals in July.TechCrunchOkra raises $12M as it brings solar power to grids in developing areasOkra Solar raised $12 million in a Series A led by One Ventures to expand its mesh-based solar grid technology for off-grid areas. The funding includes $7.85 million in equity and aims to serve regions lacking electricity, with the IEA forecasting Africa's power capacity to double to 510 GW by 2030.ImmvirxImmVirX raising $25m led by renowned healthcare VC OneVentures – ImmVirxImmVirX has announced a Series B fundraising round of up to A$25 million, led by healthcare venture capital firm OneVentures which is investing A$15 million. The funds will support the company's clinical development pipeline through 2026, following the recent dosing of its first patient in Phase 1 trials for its oncolytic virus IVX037. Dr Jeannie Joughin from OneVentures has joined ImmVirX's board to provide strategic expertise in the biopharmaceutical sector.Australian Financial ReviewOneVentures pumps up artificial heart group BiVACORSydney-based venture capital firm OneVentures is investing $18 million in heart device company BiVACOR. The funding round is intended to support the company's artificial heart development. No further details on the investment's use or timeline were disclosed.SmartCompanyOneVentures apologises twice for IWD post highlighting menOneVentures apologized twice for an International Women's Day LinkedIn post that featured nine men, after backlash called it tone-deaf. The firm's co-founder acknowledged the mistake, but critics like Jessy Wu of AfterWork Ventures want more action. The company declined further comment.